Mathias Luderer1, Falk Kiefer2,3, Andreas Reif4, Franz Moggi5. 1. Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Frankfurt, Goethe-Universität Frankfurt, Heinrich-Hoffmann-Straße 10, 60528, Frankfurt am Main, Deutschland. mathias.luderer@kgu.de. 2. Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland. 3. Feuerlein Centrum für Translationale Suchtmedizin, Heidelberg, Deutschland. 4. Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Frankfurt, Goethe-Universität Frankfurt, Heinrich-Hoffmann-Straße 10, 60528, Frankfurt am Main, Deutschland. 5. Universitätsklinik für Psychiatrie und Psychotherapie, Universität Bern, Bern, Schweiz.
Abstract
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a common comorbidity in adult patients with substance use disorders (SUDs). The diagnostics and treatment of ADHD with SUD are often a challenge, also with respect to the prescription of stimulants. Recently, a group of international experts developed a consensus paper on the diagnosis and treatment of comorbid ADHD and SUD. In addition, the German S3 guidelines on ADHD have been published, which also give advice on the treatment of ADHD in comorbid SUD. The German S3 guidelines on alcohol-related disorders and methamphetamine-related disorders also address ADHD as a comorbidity. METHODS: Summary of consensus and guideline recommendations, supplemented with the most recent literature. CONCLUSION: In recent years new findings on the comorbidity of ADHD in patients with SUD have emerged. A series of screening and diagnostic instruments have meanwhile been evaluated in this patient group. The consensus paper and various guidelines therefore provide clinicians with specific help in detecting ADHD in patients with SUD and in conducting further diagnostics and treatment of both disorders. For example, the importance of stimulants in the treatment of patients with SUD and ADHD has significantly changed and first studies on psychotherapeutic interventions specific to this comorbidity are now available.
BACKGROUND:Attention-deficit/hyperactivity disorder (ADHD) is a common comorbidity in adult patients with substance use disorders (SUDs). The diagnostics and treatment of ADHD with SUD are often a challenge, also with respect to the prescription of stimulants. Recently, a group of international experts developed a consensus paper on the diagnosis and treatment of comorbid ADHD and SUD. In addition, the German S3 guidelines on ADHD have been published, which also give advice on the treatment of ADHD in comorbid SUD. The German S3 guidelines on alcohol-related disorders and methamphetamine-related disorders also address ADHD as a comorbidity. METHODS: Summary of consensus and guideline recommendations, supplemented with the most recent literature. CONCLUSION: In recent years new findings on the comorbidity of ADHD in patients with SUD have emerged. A series of screening and diagnostic instruments have meanwhile been evaluated in this patient group. The consensus paper and various guidelines therefore provide clinicians with specific help in detecting ADHD in patients with SUD and in conducting further diagnostics and treatment of both disorders. For example, the importance of stimulants in the treatment of patients with SUD and ADHD has significantly changed and first studies on psychotherapeutic interventions specific to this comorbidity are now available.
Authors: Katelijne van Emmerik-van Oortmerssen; Geurt van de Glind; Maarten W J Koeter; Steve Allsop; Marc Auriacombe; Csaba Barta; Eli Torild H Bu; Yuliya Burren; Pieter-Jan Carpentier; Susan Carruthers; Miguel Casas; Zsolt Demetrovics; Geert Dom; Stephen V Faraone; Melina Fatseas; Johan Franck; Brian Johnson; Máté Kapitány-Fövény; Sharlene Kaye; Maija Konstenius; Frances R Levin; Franz Moggi; Merete Møller; J Antoni Ramos-Quiroga; Arild Schillinger; Arvid Skutle; Sofie Verspreet; Wim van den Brink; Robert A Schoevers Journal: Addiction Date: 2013-11-20 Impact factor: 6.526
Authors: Katelijne van Emmerik-van Oortmerssen; Geurt van de Glind; Wim van den Brink; Filip Smit; Cleo L Crunelle; Marije Swets; Robert A Schoevers Journal: Drug Alcohol Depend Date: 2011-12-30 Impact factor: 4.492
Authors: Ronald C Kessler; Lenard Adler; Minnie Ames; Olga Demler; Steve Faraone; Eva Hiripi; Mary J Howes; Robert Jin; Kristina Secnik; Thomas Spencer; T Bedirhan Ustun; Ellen E Walters Journal: Psychol Med Date: 2005-02 Impact factor: 7.723
Authors: Howard Schubiner; Karen K Saules; Cynthia L Arfken; Chris-Ellyn Johanson; Charles R Schuster; Nancy Lockhart; Ann Edwards; Judy Donlin; Eric Pihlgren Journal: Exp Clin Psychopharmacol Date: 2002-08 Impact factor: 3.157
Authors: Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes Journal: Drug Alcohol Depend Date: 2005-08-15 Impact factor: 4.492
Authors: Timothy E Wilens; Lenard A Adler; Margaret D Weiss; David Michelson; Janet L Ramsey; Rodney J Moore; Didier Renard; Kathleen T Brady; Paula T Trzepacz; Leslie M Schuh; Lisa M Ahrbecker; Louise R Levine Journal: Drug Alcohol Depend Date: 2008-04-09 Impact factor: 4.492
Authors: Geurt van de Glind; Maija Konstenius; Maarten W J Koeter; Katelijne van Emmerik-van Oortmerssen; Pieter-Jan Carpentier; Sharlene Kaye; Louisa Degenhardt; Arvid Skutle; Johan Franck; Eli-Torild Bu; Franz Moggi; Geert Dom; Sofie Verspreet; Zsolt Demetrovics; Máté Kapitány-Fövény; Melina Fatséas; Marc Auriacombe; Arild Schillinger; Merete Møller; Brian Johnson; Stephen V Faraone; J Antoni Ramos-Quiroga; Miguel Casas; Steve Allsop; Susan Carruthers; Robert A Schoevers; Sara Wallhed; Csaba Barta; Peter Alleman; Frances R Levin; Wim van den Brink Journal: Drug Alcohol Depend Date: 2013-10-05 Impact factor: 4.492
Authors: Geurt Van de Glind; Christoffer Brynte; Arvid Skutle; Sharlene Kaye; Maija Konstenius; Frances Levin; Frieda Mathys; Zsolt Demetrovics; Franz Moggi; Josep Antoni Ramos-Quiroga; Arnt Schellekens; Cleo Crunelle; Geert Dom; Wim van den Brink; Johan Franck Journal: Eur Addict Res Date: 2020-06-29 Impact factor: 3.015